| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
|
| 2 |
Bray F,Ferlay J,Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| 3 |
Herbst RS,Heymach JV,Lippman SM. Lung cancer [J]. N Engl J Med, 2008, 359(13): 1367-1380.
|
| 4 |
Allemani C,Weir HK,Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25，676，887 patients from 279 population-based registries in 67 countries (CONCORD-2)[J]. Lancet, 2015, 385(9972): 977-1010.
|
| 5 |
Rosell R,Carcereny E,Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3): 239-246.
|
| 6 |
Watanabe S,Inoue A,Nukiwa T, et al. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion[J]. Anticancer Res, 2015, 35(12): 6957-6961.
|
| 7 |
Zhou C,Wu YL,Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8): 735-742.
|
| 8 |
Han JY,Park K,Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung[J]. J Clin Oncol, 2012, 30(10): 1122-1128.
|
| 9 |
de Visser KE,Eichten A,Coussens LM. Paradoxical roles of the immune system during cancer development[J]. Nat Rev Cancer, 2006, 6(1): 24-37.
|
| 10 |
Luo Q,Gu Y,Zheng W, et al. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway[J]. Toxicol Appl Pharmacol, 2011, 251(2): 130-136.
|
| 11 |
Danielli R,Cisternino F,Giannarelli D, et al. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy[J]. Expert Opin Biol Ther, 2018, 18(sup1): 77-83.
|
| 12 |
Garaci E,Pica F,Matteucci C, et al. Historical review on thymosin alpha1 in oncology: preclinical and clinical experiences[J]. Expert Opin Biol Ther, 2015, 15 Suppl 1: S31-S39.
|
| 13 |
Jiang J,Wang X,Tian J, et al. Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials[J]. Thorac Cancer, 2011, 2(4): 213-220.
|
| 14 |
余荣，孙宇，蔡庆，等. α1胸腺肽减轻放射性肺损伤[J]. 中国肺癌杂志，2011, 14(3): 187-193.
|
| 15 |
Moody TW,Fagarasan M,Zia F, et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo[J]. Cancer Res, 1993, 53(21): 5214-5218.
|
| 16 |
Garaci E,Pica F,Serafino A, et al. Thymosin alpha1 and cancer: action on immune effector and tumor target cells[J]. Ann N Y Acad Sci, 2012, 1269: 26-33.
|
| 17 |
Wee P,Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways[J]. Cancers (Basel), 2017, 9(5)．
|
| 18 |
Li M,Ong SS,Rajwa B, et al. The SH3 domain of Lck modulates T-cell receptor-dependent activation of extracellular signal-regulated kinase through activation of Raf-1[J]. Mol Cell Biol, 2008, 28(2): 630-641.
|
| 19 |
Roskoski RJ. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors[J]. Pharmacol Res, 2014, 87: 42-59.
|
| 20 |
Knutsen AP,Freeman JJ,Mueller KR, et al. Thymosin-alpha1 stimulates maturation of CD34＋ stem cells into CD3＋4＋ cells in an in vitro thymic epithelia organ coculture model[J]. Int J Immunopharmacol, 1999, 21(1): 15-26.
|
| 21 |
Romani L,Bistoni F,Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling[J]. Blood, 2004, 103(11): 4232-4239.
|
| 22 |
Jennings RN,Grayson JM,Barton ES. Type I interferon signaling enhances CD8＋ T cell effector function and differentiation during murine gammaherpesvirus 68 infection[J]. J Virol, 2014, 88(24): 14040-14049.
|